摘要
目的探讨莫沙必利联合舍曲林治疗功能性便秘临床疗效和安全性。方法运用随机数字表法将2008年6月～2012年6月在山东大学齐鲁医院消化内科住院治疗的88例功能性便秘患者分为A组和B组,各44例。A组患者仅给予莫沙比利治疗,而B组则给予莫沙必利联合舍曲林治疗,治疗3个月比较两组患者的临床疗效和不良反应发生情况。结果 B组患者治疗总有效率(95.45%)明显高于A组(79.55%),差异有统计学意义(P<0.05),两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论莫沙必利联合舍曲林治疗功能性便秘临床疗效确切,疗效优于单用莫沙必利,具有安全可靠和不良反应少等特点。
Objective To investigate the clinical efficacy and safety of patients with functional constipation treated by Mosapride and Sertraline. Methods 88 patients with functional constipation who were in the department of gastroen- terology in Qilu hospital of Shandong university from June 2008 to June 2012 were collected, they were divided into group A and group B by random number table, with 44 cases in each group. The patients in group A were given Mosapride, while the patients in group B were given Mosapride and Sertraline. Then the clinical efficacy and abverse reactions after treatment for three months of the two groups were compared. Results The total effective rate of group B was significantly higher than group A （95.45% vs 79.55%, P 〈 0.05）. The adverse reaction rates of the two groups were not significant different （P 〉 0.05）. Conclusion The clinical efficacy of Mosapride and Sertraline is superior to patients with functional constipation only by Mosapride. It is safe and reliable and has less adverse reactions.
出处
《中国医药导报》
CAS
2013年第4期72-73,共2页
China Medical Herald
基金
国家自然科学基金资助项目(项目编号:81170352)
关键词
莫沙比利
舍曲林
功能性便秘
临床疗效
安全性
Mosapride
Sertraline
Functional constipation
Clinical efficacy
Safety
